RxSight Stock Plunges 19.6% on Missed Revenue Targets

On April 3, 2025, RxSight's stock experienced a significant drop of 19.6% in pre-market trading, reflecting investor concerns over the company's recent financial performance and revised guidance.

RxSight reported preliminary first-quarter 2025 revenue of $37.9 million, which, while representing a 28% year-over-year increase, fell short of the consensus estimate of $47.0 million. This discrepancy has raised questions about the company's growth trajectory and market expectations.

The company also revised its full-year 2025 revenue guidance, lowering it to a range of $160 million to $175 million from the previous estimate of $185 million. This adjustment suggests that RxSight is facing challenges in meeting its earlier projections, which could impact investor confidence.

Despite the revenue growth, the company's stock price decline indicates that investors are more focused on the shortfall from consensus estimates and the revised guidance. The market's reaction underscores the importance of meeting or exceeding expectations in the eyes of investors.